Vaccinex, Inc. (VCNX): Price and Financial Metrics

Vaccinex, Inc. (VCNX): $3.71

0.45 (+13.80%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

C

Add VCNX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#234 of 332

in industry

VCNX Price/Volume Stats

Current price $3.71 52-week high $13.02
Prev. close $3.26 52-week low $1.39
Day low $3.28 Volume 30,000
Day high $3.72 Avg. volume 55,340
50-day MA $3.37 Dividend yield N/A
200-day MA $5.81 Market Cap 6.41M

VCNX Stock Price Chart Interactive Chart >


Vaccinex, Inc. (VCNX) Company Bio


Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is VX15 that is in Phase Ib/II clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer, osteosarcoma, and melanoma; and Phase II clinical trials for the treatment of Huntington’s disease. The company’s preclinical development products include VX5, a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, for the treatment of MS and other autoimmune disorders; and VX25 is an investigational and bi-specific molecule for the therapeutic application of Natural Killer T cell stimulation for cancer immunotherapy. Vaccinex, Inc. was founded in 2001 and is based in Rochester, New York.


VCNX Latest News Stream


Event/Time News Detail
Loading, please wait...

VCNX Latest Social Stream


Loading social stream, please wait...

View Full VCNX Social Stream

VCNX Price Returns

1-mo 33.94%
3-mo -31.04%
6-mo -31.30%
1-year -70.71%
3-year -98.87%
5-year -99.62%
YTD -60.14%
2023 -93.12%
2022 -38.03%
2021 -49.76%
2020 -57.32%
2019 33.06%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!